Metrics
12 Record Views
- Title
- Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib
- Creators
- Pierre Fenaux - Hospital St Louis, Paris, FranceAref Al-Kali - Mayo ClinicMaria R. Baer - University of Maryland Marlene and Stewart Greenebaum Cancer CenterMikkael A. Sekeres - Cleveland ClinicGail J. Roboz - Cornell UniversityGianluca Gaidano - Università degli Studi del Piemonte Orientale “Amedeo Avogadro”Lewis R. Silverman - Mount Sinai Medical CenterBart L Scott - Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South AfricaPeter Greenberg - Stanford UniversityUwe Platzbecker - University Hospital Carl Gustav CarusDavid P. Steensma - Dana-Farber Cancer InstituteKarl A Kreuzer - University Hospital CologneLucy A. Godley - University of ChicagoRobert Collins - The University of Texas Southwestern Medical CenterEhab L. Atallah - Medical College of WisconsinNozar Azarnia - Onconova TherapeuticsGuillermo Garcia-Manero - The University of Texas MD Anderson Cancer Center
- Publication Details
- Journal of clinical oncology, Vol.33(15_suppl), pp.e18079-e18079
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Journal article
- Record Identifier
- 991031757976602976